- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03369340
Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P
A Single-center, Open-label, Randomized, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile, Pharmacodynamics, Safety and Tolerability of Four P3P Variants in Smoking Healthy Adult Subjects
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The goal of the proposed study is to evaluate the pharmacokinetic profiles of four P3P variants. Variants with two different nicotine contents (1 mg/product and 2 mg/product), two different nicotine aersol particle sizes and presence/absence of a flavoring system will be tested to identify which one would yield plasma nicotine concentrations as close as possible to those achieved after smoking a single cigarette. All of the subjects will initially use the lowest nicotine content product (P3P 3). Subject will continue the study using the three remaining products (P3P 1, P3P 2 and P3P 4) containing 2 mg nicotine/product in a randomly assigned sequence.
Two product use regimens: fixed puffing and ad libitum use will be applied to provide insight into nicotine absorption. The fixed puffing regimen with consistent use conditions across subjects will be applied in order to minimize variability. The 1 hour ad libitum use period will provide information on nicotine PK and product acceptance when subjects use the P3P according to their own puffing behavior which is closer to a real-world setting.
Safety and tolerability will also be assessed throughout the study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ticino
-
Arzo, Ticino, Svizzera, 6864
- CROSS Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Subject has signed the Informed Consent Form (ICF) and is able to understand the information provided in the ICF.
- Subject is between 21 and 65 years old.
- Subject is Caucasian.
- Smoking, healthy subject as judged by the Investigator or designee based on available assessments from the screening period.
- Subject has been smoking at least 10 commercially available cigarettes per day at least for the last 4 weeks prior to Screening Visit. Smoking status will be verified based on a urinary cotinine test (cotinine ≥ 200 ng/mL).
- Subject has been smoking for at least the last 3 years prior to Screening Visit.
- Subject does not plan to quit smoking in the next 2 months after the Screening Visit.
Exclusion criteria:
- Female subject is pregnant or breastfeeding.
- Female subject uses estrogen-containing hormonal contraception or hormone replacement therapy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Product Sequence 1
Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of: P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4 |
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
|
Comparatore attivo: Product Sequence 2
Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of: P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4 |
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
|
Comparatore attivo: Product Sequence 3
Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of: P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4 |
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
|
Comparatore attivo: Product Sequence 4
Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of: P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4 |
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
|
Comparatore attivo: Product Sequence 5
Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of: P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4 |
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
|
Comparatore attivo: Product Sequence 6
Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of: P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4 |
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Plasma Nicotine Concentration-time Profile
Lasso di tempo: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
Maximum Plasma Concentration [Cmax]
Lasso di tempo: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
Time to the Maximum Nicotine Concentration [Tmax]
Lasso di tempo: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
Area Under the Concentration-time Curve From Start of Product Use (T0 Fix) to 4 Hours [AUCfix (0-4h)]
Lasso di tempo: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Plasma Nicotine Concentration-time Profile
Lasso di tempo: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
Peak Plasma Nicotine Concentration [Cpeak]
Lasso di tempo: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
Time to Peak Plasma Nicotine Concentration [Tpeak]
Lasso di tempo: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
Trough Plasma Nicotine Concentration [Ctrough]
Lasso di tempo: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
Average of Plasma Nicotine Concentration From T0 ad Lib to 1 Hour [Caverage]
Lasso di tempo: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4
|
To measure the average of plasma nicotine concentration [Caverage], of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels
|
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4
|
Area Under the Concentration-time Curve From Start of Product Use (T0 ad Lib) to 4 Hours [AUCad Lib (0-4h)]
Lasso di tempo: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
|
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
|
AUC of Craving for a Cigarette During and After the Fixed Puffing Regimen
Lasso di tempo: During and up to 4 hours post-product use on days 1, 2, 3 and 4
|
Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).
|
During and up to 4 hours post-product use on days 1, 2, 3 and 4
|
AUC Craving for a Cigarette During and After the ad Libitum Use Period
Lasso di tempo: During and up to 4 hours post-product use on days 1, 2, 3 and 4
|
Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).
|
During and up to 4 hours post-product use on days 1, 2, 3 and 4
|
Product Evaluation
Lasso di tempo: Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
|
Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period.
Assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).
|
Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
|
Sensory Parameters
Lasso di tempo: Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
|
Measured with a Sensory Questionnaire (SQ) following the ad libitum use period.
Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).
|
Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
|
Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the Fixed Puffing Regimen Period.
Lasso di tempo: During fixed puffing product use on days 1, 2, 3 and 4
|
Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the fixed puffing regimen period.
|
During fixed puffing product use on days 1, 2, 3 and 4
|
Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the ad Libitum Use Period.
Lasso di tempo: During ad libitum product use on days 1, 2, 3 and 4
|
Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the ad libitum use period.
|
During ad libitum product use on days 1, 2, 3 and 4
|
Amount of Powder Aerosolized From P3P From the Fixed Puffing Regimen.
Lasso di tempo: Before and after fixed puffing product use on days 1, 2, 3 and 4
|
Descriptive statistics of P3P weight before use, and after use, for the fixed puffing regimen.
|
Before and after fixed puffing product use on days 1, 2, 3 and 4
|
Amount of Powder Aerosolized From P3P From the ad Libitum Use Period (Per Product Used).
Lasso di tempo: Before and after ad libitum product use on days 1, 2, 3 and 4
|
P3P weight before use, and after use, to determine the amount of powder aerosolized from P3P during Ad Libitum use (per product used).
|
Before and after ad libitum product use on days 1, 2, 3 and 4
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Milko Radicioni, MD, CROSS Research, Arzo, Ticino, Switzerland
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- P3P-PK-01-CH
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su P3P 1
-
Philip Morris Products S.A.CompletatoFarmacocineticaFederazione Russa
-
Dana-Farber Cancer InstituteNational Institute of Nursing Research (NINR)CompletatoCancro alla prostataStati Uniti
-
University of ThessalyCompletatoDanni muscolariGrecia
-
Chulalongkorn UniversityCompletatoRinite allergicaTailandia
-
University of Sao Paulo General HospitalCompletatoSindrome della vescica iperattivaBrasile
-
University of Sao Paulo General HospitalCompletato
-
Orasis Pharmaceuticals Ltd.Completato
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen... e altri collaboratoriCompletatoIpertrigliceridemiaCanada
-
Yonsei UniversityCompletatoPazienti obesi, ventilazione a un polmoneCorea, Repubblica di
-
Janssen Research & Development, LLCCompletatoLinfoma di Hodgkin recidivato o refrattarioFrancia, Germania